CA-ARCTIC-BLUE-BEVERAGES
12.4.2022 18:02:09 CEST | Business Wire | Press release
Products of the Finnish beverage company Arctic Blue Beverages succeeded nobly at the prestigious The San Francisco World Spirit Competition (SFWSC). The company's newest gins, Arctic Blue Legacy Gin and Arctic Blue Gin Rose, won double gold. Silver was awarded to the innovative oat liqueur, Arctic Blue Oat.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005706/en/
“Although we know our products rank high in taste and quality globally, this was still an overwhelming result, for a relatively small player in the global alcohol industry,” Valtteri Eroma, the CEO of Arctic Blue Beverages, rejoices.
“Developing new products is always a team effort, but the key role in the taste of Arctic Blue products plays our internationally awarded Master Distiller Asko Ryynänen. With Asko, we have developed an agile process to turn ideas effectively into award-winning products, which is now paying off,” Valtteri adds.
Arctic Blue Legacy is a barrel-aged gin sold in a unique bottle designed by Timo Sarpaneva. The product is targeted to the ultra-premium category and packed in a prestige handmade wooden gift package. It has already received the highest recognition at the International Wine and Spirit Competition (IWSC) with a gold medal and 95 points back in 2021.
Arctic Blue Gin Rose is the company's entry into the fast-growing category of pink gins. The taste profile is similar to the multi-award winning Arctic Blue Gin with hints of cinnamon rose petals in both scent and taste. The beautiful red color comes from Finnish bilberries.
Arctic Blue Oat is the world’s first gin-based oat liqueur, which was launched a year ago. It was already awarded with a bronze medal at the International Wine and Spirit Competition (IWSC) in 2021.
“Based on our experience after previous awards, this will give a great boost to the sales of our new products as well as our current products like Arctic Blue Oat. Therefore, immediately after hearing the preliminary information, we have worked hard to increase the production capacity of our products at the distillery,” says Valtteri Eroma.
Products of Arctic Blue Beverages have previously been successful in the SFWSC competition. For example in 2019 Arctic Blue Navy Strength Gin won Double Gold and the Best in Show awards at the World Spirits Awards in San Francisco.
Awards for Arctic Blue Beverages in 2022:
DOUBLE GOLD MEDAL, Arctic Blue Gin Rose (Flavoured Gin Category)
DOUBLE GOLD MEDAL, Arctic Blue Legacy Gin (Barrel Aged Gin Category)
SILVER MEDAL, Arctic Blue Oat, Finland (Other Liqueurs Category)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005706/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom